Menopausal hormone therapy and risk of ovarian cancer: Systematic review and meta-analysis

Human Reproduction Update

Volumn 13, Issue 5, 2007, Pages 453-463

  Greiser, Claudia M ^a   Greiser, Eberhard M ^a,b   Dören, Martina ^c  

^a EpiConsult GmbH   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Estrogen (progestin) therapy; Hormone replacement therapy; Menopausal hormone therapy; Ovarian cancer; Risk factor

Indexed keywords

ESTROGEN; GESTAGEN;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; ENDOMETRIOID CARCINOMA; ETHNIC DIFFERENCE; EUROPE; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; META ANALYSIS; MUCINOUS CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNITED STATES;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 34548153826     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmm012     Document Type: Review

References (81)

1. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM, Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. JAMA 2003;290:1739-1748.
2. Annegers JF, Strom H, Decker DG, Dockerty MB, ÓFallon WM. Ovarian cancer. Incidence and case-control study. Cancer 1979;43 723-729.
3. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 2004;112:130-134.
4. Beard CM, Hartmann LC, Atkinson EJ, ÓBrien PC, Malkasian GD, Keeney GL, Melton LJ, III. The epidemiology of ovarian cancer: A population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 2000;10:14-23.
5. Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer, J Epidemiol Biostatistics 1999;4:191-215.
6. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology 1993;4:218-228.
7. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: A case-control study. Br J Cancer 1989;60:592-598.
8. Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C. Relationship between postmenopausal hormone replacement and ovarian cancer. JAMA 2001;285:3089 [letter].
9. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997:145:536-545.
10. Chiaffarino F, Peluchi C, Parazzini F, Negri E, Franceschi S, Salamini R. Conti E, Montella M, La Vecchia C. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001;12:337-341.
11. Col NF. The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms. Am J Med 2605;118(Suppl):155-162.
12. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement and risk of epithelial ovarian cancer. J Clin Epidemiol 2005;53:367-375.
13. Cramer DW, Hutchinson GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-716.
14. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007;96:151-156.
15. Ettinger B, Barrett-Connor E, Hoq LA. Vader JP, Dubois RW. When is it appropriate to prescribe, postmenopausal hormone therapy? Menopause 2006;13:404-410.
16. Farquhar CM, Marjoribanks J, Lethaby A. Lamberts Q, Suckling JA, The Cochrane HT Study Group. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005, 3 (Art. No.: CD004143. DOI: 0.1002/14651858.CD004143.pub2). (16 May 2007, date last accessed).
17. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: A systematic analysis from a network of case-control studies. Int J Cancer 2003;105 408-412.
18. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004;15:100-104.
19. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis. Obstet Gynecol 1998:92:472-479.
20. Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, Bock JE, Blaakaer J. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Int Med 2004;164: 2253-2259.
21. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of breast cancer: A meta-analysis of epidemiological studies and randomized controlled trials. Human Reprod Update 2005;11 561-573.
22. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM. Atkins D for the Methods Work Group, Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force. A review of the process. Am J Prev Med 2001:20:21-35.
23. Hartge P, Hoover P, McGowan L, Lesher L, Norris HJ. Menopause and ovarian cancer, Am J Epidemiol 1988;127:990-999.
24. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-1986. Am J Public Health 1988;78:1479-1481.
25. Hempling RE, Wong C, Piver S, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 1997;89 1012-1016.
26. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
27. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
28. Hildreth NG, Kelsey JL, LiVolsi VA, Fischer DB, Holford TR, Mostow ED, Schwan PE, White C. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981:114:398-405.
29. Hing E, Brett KM. Clianges in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006;108:33-40.
30. Hunt & Vessey M, McPherson & Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy, Br J Obstet Gynaecol 1987;94:620-635.
31. IARC Working Group. Combined Estrogen-Progestogen Menopausal Therapy (Group 1). 5. Summary of Data Reported and Evaluation. http://monographs.iarc.fr/ENG/Meetings/91-menop-ther.pdf (2006). (16 May 2007, date last accessed).
32. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world: J Clin Oncol 2006;24:2137-2150.
33. Kaufman DW, Kelly JP, Welch WR, Rosenberg L, Stolley PD, Warshauer ME, Lewis J, Woodruff J, Shapiro S. Noncontraceptive estrogen use and epithelial ovarian cancer, Am J Epidemiol 1989;130:1142-1151.
34. Kiani F, Knutsen S, Singh P, Ursin G, Fraser G. Dietary risk factors for ovarian cancer the adventist health study (United States). Cancer Causes Control 2006;17:137-146.
35. Katsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan LB et al. Hormone replacement therapy and the risk of ovarian cancer on BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006;100:83-88.
36. Kumle M, Weiderpass E, Braaten T, Adami H-O, Lund E. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: The Norwegian-Swedish Womens lifestyle and health cohort study. Br J Cancer 2004;90:1396-1391.
37. Kurian AW, Balise RB, McGuire V, Whittemore AS. Histological types of epithelial ovarian cancer: Have they different risk factors? Gynecol Oncol 2005;96:520-530.
38. Lacey JV, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP diet and health study cohort. J Natl Cancer Inst 2006;98:1397-1405.
39. Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C, Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002a;288:334-341.
40. Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Estrogen replacement therapy and risk of ovarian cancer in postmenopausal women. JAMA 2002b;288:2539 [letter].
41. La Vecchia C, Franceschi S. Noncontraceptive estrogen use and the occurence of ovarian cancer. J Natl Cancer Inst 1982;69:1207 [letter].
42. Lee NC, Wingo PA, Peterson HB, Rubin GL, Sattin RW. Estrogen therapy and the risk of breast ovarian, and endometrial cancer. In: Mastroianni LJ, Paulsen C (eds). Aging, Reproduction and the Climacteric, New York: Plenum Press, 1986, 287-303.
43. Mills PK, Riordan DG, Cress RD. Epithelial ovarian cancer by invasiveness and cell type in the Central Valley of California. Gynecol Oncol 2004;95:215-225.
44. Mills PK, Riordan DG, Cress RD, Goldsmith DF, Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 2005;29:124-132.
45. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001:11:568-574.
46. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuk A. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005;193: 76-82.
47. Morabia A, Constanza MC. Recent reversal of trends in hormone therapy use in a European population. Menopause 2006;13:111-115.
48. Mori M, Nishida T, Sugiyama T, Komai K, Yakushiji M, Fukuda K, Tanaka T, Yokoyama M, Sugimori H. Anthropometric and other risk factors for ovarian cancer: In a case-control study. Jpn J Cancer Res 1998; 89:246-253.
49. National Heart, Lung, and Blood Institute. International Position Paper on Women's Realth and Menopause: A Comprehensive Approach. Office of Research on Women's Health, National Institute of Health and Giovanni Lorenzini Medical Science Foundation. http://www.nhlbi.nih.gov/ health/prof/heart/other/wm_menop.pdf (2002). (16 May 2007, date last accessed).
50. Negri E, Tzonou A, Beral V, Lagiou P, Trichopoulos, Parazzini F, Franceschi F, Booth M, La Vecchia C. Hormonal therapy for menopausal and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999;80:848-851.
51. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: Scientific review, JAMA 2002;288 872-881.
52. Olsson H, Bladström A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 2003;102:565-570.
53. Parazzini F, La Vecchia C, Negri E, Villa A. Estrogen replacement therapy and ovarian cancer risk, Int J Cancer 1994;57 135-136.
54. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-332.
55. Petitti DB. Statistical methods in meta-analysis. In: Pettiti DB (ed). Meta-Analysis, Decision Analysis, and Cost-Effactiveness Analysis, 2nd edn. New York: Oxford University Press, 2000, 63-67, 111-113, 213-224.
56. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek study. Obstet Gynecol 1987;70:289-293.
57. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: A population-based case-control study. Fertil Steril 2004a;82:186-195.
58. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004b;23:6379-6391.
59. Polychronopoulou A, Tzonou A, Hsieh C-C, Kaprinis GM, Rebelakos A, Toupadaki N, Trichopoulos D. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993;55:402-407.
60. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormone replacement therapy, Finland 1994-1997. Cancer Causes Control 2001;12:141-115.
61. Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, Quinn MA, Green AC. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999;81:559-563.
62. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Homer MJ, Howlader N (eds). SEER Cancer Statistics Review, 1975-2003. National Cancer Institute. Bethesda, MD, based on November 2005 SEER data submission, posted to the SEER web site. http://seer.cancer.gov/csr/1975_2003/(2006). (16 May 2007, date last accessed).
63. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001;83 575-585.
64. Riman T, Dickman PW, Nilsson S, Correia N. Nordlinder H, Magnusson CM, Persson IR. Risk factors for invasive epithelial ovarian cancer: Results from a Swedish case-control study. Am J Epidemiol 2002a,156 363-373.
65. Riman T. Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM. Weiderpass E, Persson IR et al. Hormone replacement and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002b;94:497-504.
66. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996;63:254-257.
67. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786.
68. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Am J Epidemiol 1996;144:363-372.
69. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.
70. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001;95 370-374.
71. Salazar-Martinez E, Lucano-Ponce EC, Lira-Lira GG, Escudero-de los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 1999;59:3658-3662.
72. Sit ASY, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002;86:118-123.
73. Smith EM, Sowers MF, Burns TL. Effects of smoking on the development of female reproductive cancers. J Natl Cancer Inst 198473 371-376.
74. Steinberg KK, Thacker SB, Smith SJ, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265:1985-1990 [and Erratum in: JAMA 1991;266:1362].
75. The WHO Collaborative Study of Neoplasia and Steroid Contraception. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. In J Cancer 1991;49:191-195
76. The Womens' Health Initiative Scientific Resources Website. http://www.whiscience.org/publication. (16 May 2007, date last accessed).
77. Tung K-H, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AMY, Terada KY, Carney ME, Sobin LH. Reproductive factors and epithelial ovarian cancer risk by histologic type: A multiethnic case-control study. Am J Epidemiol 2003;158:629-638.
78. U.S. Preventive Service Task Force. Hormone therapy for the prevention of chronic conditions in postmenopaual women: Recommendations from the U.S. Preventive Service Task Force. Ann Int Med 2005;142: 855-860.
79. Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Dating JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982;68:95-98.
80. Whittemore AS, Harris F, Itnyre J. The Collaborative Ovarian Cancer Group Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-1203.
81. Wysowski, DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995;8:6-10.